IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice

American Journal of Respiratory and Critical Care Medicine

Volumn 160, Issue 6, 1999, Pages 2040-2047

  Chmiel, James F ^a   Konstan, Michael W ^a   Knesebeck, Jeanne E ^a   Hilliard, Jay B ^a   Bonfield, Tracey L ^a   Dawson, Deborah V ^a   Berger, Melvin ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 10;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIOLOGY; BRONCHITIS; CONTROLLED STUDY; CYSTIC FIBROSIS; GRAM NEGATIVE INFECTION; HISTOPATHOLOGY; INFLAMMATION; KNOCKOUT MOUSE; LUNG LAVAGE; MALE; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

EID: 0033456217     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.160.6.9901043     Document Type: Article

References (36)

1. Davis, P. B., M. Drumm, and M. W. Konstan. 1996. Cystic fibrosis. State of the art. Am. J. Respir. Crit. Care Med. 154:1229-1256.
2. Konstan, M. W., and M. Berger. 1993. Infection and inflammation of the lung in cystic fibrosis. In P. B. Davis, editor. Cystic Fibrosis. Marcel Dekker, New York. 219-276.
3. Bonfield, T. L., J. R. Panuska, M. W. Konstan, K. A. Hilliard, J. B. Hilliard, H. Ghnaim, and M. Berger. 1995. Inflammatory cytokines in cystic fibrosis lungs. Am. J. Respir. Crit. Care Med. 152:2111-2118.
4. Bonfield, T. L., M. W. Konstan, P. Burfeind, J. R. Panuska, J. B. Hilliard, and M. Berger. 1995. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is down-regulated in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 13:257-261.
5. + T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR). Clin. Exp. Immunol. 106:374-388.
6. Florentino, D. F., A. Zlotnik, T. R. Mosmann, M. Howard, and A. O'Garra. 1991. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147:3815-3822.
7. Konstan, M. W., and M. Berger. 1997. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr. Pulmonol. 24:137-142.
8. Kuhn, R., J. Lohler, D. Rennick, K. Rajewsky, and W. Muller. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75:263-274.
9. Borish, L., A. Aarons, J. Rumbyrt, P. Cvietusa, J. Negri, and S. Wenzel. 1996. Interleukin-10 regulation in normal subjects and patients with asthma. J. Allergy Clin. Immunol. 97:1288-1296.
10. Donnelly, S. C., R. M. Strieter, R. T. Reid, S. L. Kunkel, M. D. Burdick, I. Armstrong, A. Mackenzie, and C. Haslett. 1996. The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with the adult respiratory distress syndrome. Ann. Intern. Med. 125:191-196.
11. Mulligan, M. S., M. L. Jones, A. A. Vaporciyan, M. C. Howard, and P. A. Ward. 1993. Protective effects of IL-4 and IL-10 against immune complex-induced lung injury. J. Immunol. 151:5666-5674.
12. Zuany-Amorim, C., S. Haile, D. Leduc, C. Dumarey, M. Huerre, B. B. Vargaftig, and M. Pretolani. 1995. Interleukin-10 inhibits antigen-induced cellular recruitment into the airways of sensitized mice. J. Clin. Invest. 95:2644-2651.
13. Shanley, T. P., H. Schmal, H. P. Friedl, M. L. Jones, and P. A. Ward. 1995. Regulatory effects of intrinsic IL-10 in IgG immune complex-induced lung injury. J. Immunol. 154:3454-3460.
14. Greenberger, M. J., R. M. Strieter, S. L. Kunkel, J. M. Danforth, R. E. Goodman, and T. J. Standiford. 1995. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J. Immunol. 155:722-729.
15. Auerbach, H. S., M. Williams, J. A. Kirkpatrick, and H. R. Colten. 1985. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 2:686-688.
16. Eigen, H., B. J. Rosenstein, S. FitzSimmons, and D. V. Schidlow. 1995. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J. Pediatr. 126:515-523.
17. Konstan, M. W., K. M. Vargo, and P. B. Davis. 1990. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection: implications for antiinflammatory therapy in cystic fibrosis. Am. Rev. Respir. Dis. 141:186-192.
18. Konstan, M. W., P. J. Byard, C. L. Hoppel, and P. B. Davis. 1995. Effect of high-dose ibuprofen in patients with cystic fibrosis. N. Engl. J. Med. 332:848-854.
19. van Heeckeren, A., R. Walenga, M. W. Konstan, T. Bonfield, P. B. Davis, and T. Ferkol. 1997. Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa. J. Clin. Invest. 100:2810-2815.
20. Scheinman, R. I., A. Gualberto, C. M. Jewell, J. A. Cidlowski, and A. S. Baldwin, Jr. 1995. Characterization of mechanisms involved in transrepression of NF-κB by activated glucocorticoid receptors. Mol. Cell Biol. 15:943-953.
21. Scheuren, N., H. Bang, T. Munster, K. Brune, and A. Pahl. 1998. Modulation of transcription factor NF-κB by enantiomers of the nonsteroidal drug ibuprofen. Br. J. Pharmacol. 123:645-652.
22. Cash, H. A., D. E. Woods, B. McCullough, W. G. Johanson, Jr., and J. A. Bass. 1979. A rat model of chronic respiratory infection with Pseudomonas aeruginosa. Am. Rev. Respir. Dis. 119:453-459.
23. Starke, J. R., M. S. Edwards, C. Langston, and C. J. Baker. 1987. A mouse model of chronic pulmonary infection with Pseudomonas aeruginosa and Pseudomonas cepacia. Pediatr. Res. 22:698-702.
24. Morissette, C., E. Skamene, and F. Gervais. 1995. Endobronchial inflammation following Pseudomonas aeruginosa infection in resistant and susceptible strains of mice. Infect. Immun. 63:1718-1724.
25. Rennard, S. I., G. Basset, D. Lecossier, K. M. O'Donnell, P. Pinkston, P. G. Martin, and R. G. Crystal. 1986. Estimation of volume of epithelial lining fluid recovered by lavage using urea as a marker of dilution. J. Appl. Physiol. 60:532-538.
26. Ghosh, M., J. E. Grizzle, and P. K. Sen. 1973. Nonparametric methods in longitudinal studies. J. Am. Stat. Assoc. 68:29-36.
27. Dawson, D. V., and I. C. Siegler. 1996. Approaches to the nonparametric analysis of limited longitudinal data sets. Exp. Aging Res. 22:33-57.
28. Conover, W. J. 1980. Practical Nonparametric Statistics, 2nd ed. John Wiley and Sons, New York. 1-493.
29. Khan, T. Z., J. S. Wagener, T. Bost, J. Martinez, F. J. Accurso, and D. W. H. Riches. 1995. Early pulmonary inflammation in infants with cystic fibrosis. Am. J. Respir. Crit. Care Med. 151:1075-1082.
30. Noah, T. L., H. R. Black, P.-W. Cheng, R. E. Wood, and M. W. Leigh. 1997. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J. Infect. Dis. 175:638-647.
31. Remick, D. G., S. J. Garg, D. E. Newcomb, G. Wollenberg, T. K. Huie, and G. L. Bolgos. 1998. Exogenous interleukin-10 fails to decrease the mortality or morbidity of sepsis. Crit. Care Med. 26:895-904.
32. Yu, H., M. Hanes, C. E. Chrisp, J. C. Boucher, and V. Deretic. 1998. Microbial pathogenesis in cystic fibrosis: pulmonary clearance of a mucoid Pseudomonas aeruginosa and inflammation in a mouse model of repeated respiratory challenge. Infect Immun. 66:280-288.
33. Sawa, T., D. B. Corry, M. A. Gropper, M. Ohara, K. Kurahashi, and J. P. Wiener-Kronish. 1997. IL-10 improves lung injury and survival in Pseudomonas aeruginosa pneumonia. J. Immunol. 159:2858-2866.
34. Wang, P., P. Wu, M. I. Siegel, R. W. Egan, and M. M. Billah. 1995. Interleukin (IL)-10 inhibits nuclear factor kappa B (NFκB) activation in human monocytes: IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J. Biol. Chem. 270:9558-9563.
35. Lentsch, A. B., T. P. Shanley, V. Sarma, and P. A. Ward. 1997. In vivo suppression of NF-κB and preservation of IκBα by interleukin-10 and interleukin-13. J. Clin. Invest. 100:2443-2448.
36. DiMango, E., A. J. Ratner, R. Bryan, S. Tabibi, and A. Prince. 1998. Activation of NF-κB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J. Clin. Invest. 101:2598-2605.